ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 259

Prevalence of Attention Deficit Hyperactivity Disorder Among Patients with Fibromyalgia

Sebastian Moyano1, Waleska Berrios2, Ignacio Javier Gandino3, Angel Golimstok4, Javier Rosa5 and Enrique R Soriano6, 1Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, 2Memory and Behavior Disorders Unit - Neurology Department, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 3Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina, 4Memory and Behavior Disorders Unit - Neurology Department, Hospital Italiano, Buenos Aires, Argentina, 5Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Capital Federal, Argentina, 6Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Cognitive dysfunction, fibromyalgia, memory and neurology, Vitamin D

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 21, 2018

Title: Fibromyalgia and Other Clinical Pain Syndromes Poster

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Chronic diseases involve cognitive aspects. Attention deficit hyperactivity disorder (ADHD) is a chronic condition, marked by persistent inattention, impaired concentration, hyperactivity, impulsivity, emotional lability, anxiety and disorganized behavior. Fibromyalgia (FM) includes a range of symptoms affecting memory, attention and concentration. High rates of comorbidity between ADHD and FM have been reported, as well as some evidence that patients with both conditions experience heightened symptom severity. In addition, recent studies suggest that vitamin D deficiency is associated with cognitive impairment.

Methods: Consecutive patients, older than 18 years, with diagnosis of fibromyalgia (2010 ACR criteria) seen at the outpatient Rheumatology Unit between May 2016 and April 2017, were included. During the inclusion visit the following data were collected: Revised Fibromyalgia Impact Questionnaire (FIQ-R), HAQ-A (Health Auto Questionnaire-simplified, Argentine validation); pain (Visual Analogue Scale, VAS), fatigue (VAS) and serum 25 -hydroxyvitamin D (25(OH)D) level. During the Neurology visit, the following tests were performed: Conners Continuous Performance Test II (CPT II), Wender-Utah Rating Scale (WURS) and Structured Clinical Interview for Personality Disorders (SCID-II). Descriptive statistics were calculated. Correlations were calculated between CPT II and pain, fatigue, FIQ-R, HAQ-A and 25(OH)D, using Spearman’s test.

Results: 37 patients with FM were included. Patients’ characteristics are shown in table 1. 73% (n=27) of the patients tested positive for adult ADHD. In 40.7% (11/27) of them, the diagnosis had been missed in childhood. Participants with both FM and a positive adult ADHD screening test did not score significantly higher on the FIQ-R (54.9, SD= 16.3 vs 48.8, SD= 11,3; p= 0.3320) and did not have lower vitamin D levels (27,4 ng/ml, SD= 13,1 vs 36,7 ng/ml, SD= 9,6; p= 0.1050). There was a very good positive correlation between ADHD and fatigue (r= -0.9607; p= 0.0086). No association was found between ADHD and severity of perceived cognitive symptoms (p= 0,673). There was no correlation with pain (r= 0.1688 p=0.3325), HAQ-A (r= 0.1340; p= 0.4429) or vitamin D level (r= -0.3211; p=0.1176). No correlation was observed between vitamin D levels and FIQ-R (r= -0.1848; p= 0.3662). The most frequent personality disorders found were narcissism (32,4%) and obsessive-compulsive disorder (32,4%).

Conclusion: The co-occurrence of adult ADHD in FM was highly prevalent. The diagnosis had been often overlooked in childhood. ADHD was associated with fatigue but not with pain, disease impact or functional capacity. Vitamin D levels were no associated with disease impact or dyscognition. Patients with FM should be assessed for the presence of adult ADHD. More investigations are needed to understand the impact of cognitive disorders in FM.

Table 1.

Characteristics n= 37
Female, n (%) 34 (92)
Age (years), mean (SD) 58.5 (13.4)
Time from diagnosis (years), mean (SD) 3.9 (3.9)
HAQ-A, mean (SD) 0.74 (0.52)
Pain (VAS, 0-100), mean (SD) 68.6 (22.8)
Fatigue (VAS, 0-100), mean (SD) 72.2 (27.2)
FIQ-R, mean (SD) 53.4 (15.2)
25(OH)D, ng/ml, mean (SD) 29.9 (12.5)
Cognitive complaint, n (%) 25 (67.6)

Disclosure: S. Moyano, None; W. Berrios, None; I. J. Gandino, None; A. Golimstok, None; J. Rosa, None; E. R. Soriano, AbbVie, Bristol-Myers Squibb, GSK, Janssen, Novartis, Pfizer Inc, Roche, UCB, 2,AbbVie, Bristol-Myers Squibb, Eli Lilly, GSK, Janssen, Novartis, Pfizer Inc, Roche, Sanofi, UCB, 5,AbbVie, Bristol-Myers Squibb, Eli Lilly, Janssen, Novartis, Pfizer Inc, Roche, Sandoz, UCB, 8.

To cite this abstract in AMA style:

Moyano S, Berrios W, Gandino IJ, Golimstok A, Rosa J, Soriano ER. Prevalence of Attention Deficit Hyperactivity Disorder Among Patients with Fibromyalgia [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/prevalence-of-attention-deficit-hyperactivity-disorder-among-patients-with-fibromyalgia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/prevalence-of-attention-deficit-hyperactivity-disorder-among-patients-with-fibromyalgia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology